Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tom Matton
Correction To: Unexpected Benefit From Alpelisib and Fulvestrant in a Woman With Highly Pre-Treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
Clinical Drug Investigation
Medicine
Pharmacology
Related publications
Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer
Cancer Discovery
Oncology
Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Developing a Prediction Model for Benefit From Fulvestrant in Heavily Pretreated Metastatic Breast Cancer Patients
Breast Cancer Research
Cancer Research
Oncology
Pcn180 - Pharmacoeconomic Assessment of Fulvestrant Versus Dd (Doxorubicin, Docetaxel) Therapy in Postmenopausal Women With Metastatic Er (+) Her2 (-) Breast Cancer in Ukraine
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer
PLoS ONE
Multidisciplinary
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
Frontiers in Oncology
Cancer Research
Oncology
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3
European Journal of Cancer
Cancer Research
Oncology
